(Q35625453)

9 August 2017

title

5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment (English)

1 reference

9 August 2017

Pinkerton CR

1

1 reference

9 August 2017

Williams D

2

1 reference

9 August 2017

Wootton C

3

1 reference

9 August 2017

Meller ST

4

1 reference

9 August 2017

McElwain TJ

5

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 August 1990

1 reference

Archives of Disease in Childhood

9 August 2017

published in

1 reference

9 August 2017

volume

65

1 reference

9 August 2017

issue

8

1 reference

9 August 2017

page(s)

822-825

1 reference

Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.

9 August 2017

cites work

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1792498

The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.

27 July 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1792498

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

27 July 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1792498

The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting

27 July 2018

1 reference

12 December 2020

ONDANSETRON WITH AND WITHOUT DEXAMETHASONE TO TREAT CHEMOTHERAPY-INDUCED EMESIS

1 reference

12 December 2020

Adverse reaction to 5-HT3 antagonist ICS 205930

1 reference

12 December 2020

PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST

1 reference

12 December 2020

First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis

1 reference

12 December 2020

The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting

1 reference

12 December 2020

Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1136/ADC.65.8.822

1 reference

9 August 2017

1 reference

9 August 2017

1 reference